ALKS Quote, Financials, Valuation and Earnings

Avadel Pharmaceuticals PLC has a net margin of 34.07% compared to Alkermes PLC's net margin of -10%. Alkermes PLC's return on equity of 28.24% beat Avadel Pharmaceuticals PLC's return on equity of -63.43%.

Alkermes PLC has a consensus price target of $39.71, signalling upside risk potential of 42.65%. On the other hand Avadel Pharmaceuticals PLC has an analysts' consensus of $17.70 which suggests that it could grow by 101.82%. Given that Avadel Pharmaceuticals PLC has higher upside potential than Alkermes PLC, analysts believe Avadel Pharmaceuticals PLC is more attractive than Alkermes PLC.

Alkermes PLC has a beta of 0.389, which suggesting that the stock is 61.101% less volatile than S&P 500. In comparison Avadel Pharmaceuticals PLC has a beta of 1.518, suggesting its more volatile than the S&P 500 by 51.847%.

Alkermes PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avadel Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes PLC pays -- of its earnings as a dividend. Avadel Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Alkermes PLC quarterly revenues are $430M, which are larger than Avadel Pharmaceuticals PLC quarterly revenues of $50.4M. Alkermes PLC's net income of $146.5M is higher than Avadel Pharmaceuticals PLC's net income of -$5M. Notably, Alkermes PLC's price-to-earnings ratio is 12.83x while Avadel Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes PLC is 3.03x versus 4.93x for Avadel Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Jazz Pharmaceuticals PLC has a net margin of 34.07% compared to Alkermes PLC's net margin of 17.56%. Alkermes PLC's return on equity of 28.24% beat Jazz Pharmaceuticals PLC's return on equity of 14.39%.

Alkermes PLC has a consensus price target of $39.71, signalling upside risk potential of 42.65%. On the other hand Jazz Pharmaceuticals PLC has an analysts' consensus of $192.22 which suggests that it could grow by 73.49%. Given that Jazz Pharmaceuticals PLC has higher upside potential than Alkermes PLC, analysts believe Jazz Pharmaceuticals PLC is more attractive than Alkermes PLC.

Alkermes PLC has a beta of 0.389, which suggesting that the stock is 61.101% less volatile than S&P 500. In comparison Jazz Pharmaceuticals PLC has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.096%.

Alkermes PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes PLC pays -- of its earnings as a dividend. Jazz Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Alkermes PLC quarterly revenues are $430M, which are smaller than Jazz Pharmaceuticals PLC quarterly revenues of $1.1B. Alkermes PLC's net income of $146.5M is lower than Jazz Pharmaceuticals PLC's net income of $191.1M. Notably, Alkermes PLC's price-to-earnings ratio is 12.83x while Jazz Pharmaceuticals PLC's PE ratio is 12.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes PLC is 3.03x versus 1.75x for Jazz Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

Medtronic PLC has a net margin of 34.07% compared to Alkermes PLC's net margin of 15.61%. Alkermes PLC's return on equity of 28.24% beat Medtronic PLC's return on equity of 8.56%.

Alkermes PLC has a consensus price target of $39.71, signalling upside risk potential of 42.65%. On the other hand Medtronic PLC has an analysts' consensus of $96.83 which suggests that it could grow by 15.06%. Given that Alkermes PLC has higher upside potential than Medtronic PLC, analysts believe Alkermes PLC is more attractive than Medtronic PLC.

Alkermes PLC has a beta of 0.389, which suggesting that the stock is 61.101% less volatile than S&P 500. In comparison Medtronic PLC has a beta of 0.794, suggesting its less volatile than the S&P 500 by 20.554%.

Alkermes PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Medtronic PLC offers a yield of 3.33% to investors and pays a quarterly dividend of $0.70 per share. Alkermes PLC pays -- of its earnings as a dividend. Medtronic PLC pays out 99.73% of its earnings as a dividend. Medtronic PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alkermes PLC quarterly revenues are $430M, which are smaller than Medtronic PLC quarterly revenues of $8.3B. Alkermes PLC's net income of $146.5M is lower than Medtronic PLC's net income of $1.3B. Notably, Alkermes PLC's price-to-earnings ratio is 12.83x while Medtronic PLC's PE ratio is 25.58x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes PLC is 3.03x versus 3.29x for Medtronic PLC. Usually stocks with elevated PS ratios are considered overvalued.

Perrigo Co PLC has a net margin of 34.07% compared to Alkermes PLC's net margin of -3.91%. Alkermes PLC's return on equity of 28.24% beat Perrigo Co PLC's return on equity of -3.76%.

Alkermes PLC has a consensus price target of $39.71, signalling upside risk potential of 42.65%. On the other hand Perrigo Co PLC has an analysts' consensus of $34.60 which suggests that it could grow by 37.19%. Given that Alkermes PLC has higher upside potential than Perrigo Co PLC, analysts believe Alkermes PLC is more attractive than Perrigo Co PLC.

Alkermes PLC has a beta of 0.389, which suggesting that the stock is 61.101% less volatile than S&P 500. In comparison Perrigo Co PLC has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.326%.

Alkermes PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perrigo Co PLC offers a yield of 4.43% to investors and pays a quarterly dividend of $0.29 per share. Alkermes PLC pays -- of its earnings as a dividend. Perrigo Co PLC pays out -88.77% of its earnings as a dividend.

Alkermes PLC quarterly revenues are $430M, which are smaller than Perrigo Co PLC quarterly revenues of $1.1B. Alkermes PLC's net income of $146.5M is higher than Perrigo Co PLC's net income of -$44.5M. Notably, Alkermes PLC's price-to-earnings ratio is 12.83x while Perrigo Co PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes PLC is 3.03x versus 0.79x for Perrigo Co PLC. Usually stocks with elevated PS ratios are considered overvalued.